Intentional Induction of Mixed Chimerism and Achievement of Antitumor Responses after Nonmyeloablative Conditioning Therapy and HLA-Matched Donor Bone Marrow Transplantation for Refractory Hematologic Malignancies

Biology of Blood and Marrow Transplantation

Volumn 6, Issue 3 A, 2000, Pages 309-320

  Spitzer, Thomas R ^a,b   McAfee, Steven ^a   Sackstein, Robert ^a   Colby, Christine ^a   Toh, Han Chong ^a   Mulkani, Pratik ^a   Saidman, Susan ^b   Weymouth, Dina ^b   Preffer, Frederic ^b   Poliquin, Cathleen ^a   Foley, Alicia ^a   Cox, Benjamin ^a   Andrews, David ^b   Sachs, David H ^a   Sykes, Megan ^a  

^a HARVARD MEDICAL SCHOOL   (United States)

^b MASSACHUSETTS GENERAL HOSPITAL   (United States)

Author keywords

Allogeneic; Bone marrow transplantation; Hematologic malignancies; Mixed chimerism; Nonmyeloablative

Indexed keywords

ANTINEOPLASTIC AGENT; CYCLOPHOSPHAMIDE; CYCLOSPORIN; HLA ANTIGEN; LYMPHOCYTE ANTIBODY;

ADULT; ALLOTRANSPLANTATION; ANIMAL; ANIMAL MODEL; ARTICLE; BLOOD DISEASE; BONE MARROW TRANSPLANTATION; CELL SURVIVAL; CHEMICALLY INDUCED DISORDER; CLINICAL TRIAL; DISEASE FREE SURVIVAL; DRUG RESISTANCE; FEMALE; FOLLOW UP; GENOTYPE; GRAFT SURVIVAL; GRAFT VERSUS HOST REACTION; GRAFT VERSUS LEUKEMIA EFFECT; HEART DISEASE; HISTOCOMPATIBILITY; HUMAN; IMMUNOLOGY; IMMUNOSUPPRESSIVE TREATMENT; LEUKOCYTE TRANSFUSION; MALE; MIDDLE AGED; MORTALITY; MOUSE; MULTIMODALITY CANCER THERAPY; PATHOLOGY; PHENOTYPE; RADIATION EXPOSURE; REMISSION; REPRODUCIBILITY; SALVAGE THERAPY; SURVIVAL; T LYMPHOCYTE; THYMUS; TRANSPLANTATION; TREATMENT OUTCOME;

ADULT; ANIMALS; ANTILYMPHOCYTE SERUM; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; BONE MARROW TRANSPLANTATION; CELL SURVIVAL; COMBINED MODALITY THERAPY; CYCLOPHOSPHAMIDE; CYCLOSPORINE; DISEASE-FREE SURVIVAL; DRUG RESISTANCE, NEOPLASM; FEMALE; FOLLOW-UP STUDIES; GENOTYPE; GRAFT ENHANCEMENT, IMMUNOLOGIC; GRAFT SURVIVAL; GRAFT VS HOST DISEASE; GRAFT VS LEUKEMIA EFFECT; HEART DISEASES; HEMATOLOGIC NEOPLASMS; HISTOCOMPATIBILITY; HLA ANTIGENS; HUMANS; LEUKOCYTE TRANSFUSION; MALE; MICE; MIDDLE AGED; MODELS, ANIMAL; PHENOTYPE; REMISSION INDUCTION; REPRODUCIBILITY OF RESULTS; SALVAGE THERAPY; SURVIVAL ANALYSIS; T-LYMPHOCYTES; THYMUS GLAND; TRANSPLANTATION CONDITIONING; TRANSPLANTATION, HOMOLOGOUS; TREATMENT OUTCOME;

EID: 0033642531     PISSN: 10838791     EISSN: None     Source Type: Journal    
DOI: 10.1016/S1083-8791(00)70056-5     Document Type: Article

References (38)

1. Ildstad ST, Sachs DH. Reconstitution with syngeneic plus allogeneic or xenogeneic bone marrow leads to specific acceptance of allografts or xenografts. Nature. 1984;30:168-170.
2. Ildstad ST, Wren SM, Bluestone JA, Barbieri SA, Stephany D, Sachs DH. Effect of selective T cell depletion of host and/or donor bone marrow lymphopoietic repopulation, tolerance, and graft-versus-host disease in mixed allogeneic chimeras (B10 + B10.D2-E10). J Immunol. 1984;136:28-33.
3. Sharabi Y, Sachs DH. Mixed chimerism and permanent specific transplantation tolerance induced by a non lethal preparative regimen. J Exp Med. 1989;169:493-502.
4. Sharabi Y, Abraham VS, Sykes M, Sachs DH. Mixed allogeneic chimeras prepared by a non-myeloablative regimen: requirement for chimerism to maintain tolerance. Bone Marrow Transplant. 1992;9:191-197.
5. Kawai T, Cosimi AB, Colvin RB, et al. Mixed allogeneic chimerism and renal allograft tolerence in cynomolgus monkeys. Transplantation. 1995;59:256-252.
6. Sykes M, Szot GL, Swenson K, Pearson DA. Induction of high levels of allogeneic hematopoietic reconstitution and donor-specific tolerance without myelosuppressive conditioning. Nat Med. 1997;3:783-787.
7. Pelot MR, Pearson DA, Swenson K, Zhao G, Sachs J, Yang Y-G, Sykes M. Lymphohematopoietic graft-vs.-host reactions can be induced without graft-vs.-host disease in murine mixed chimeras established with a cyclophosphamide-based nonmyeloablative conditioning regimen. Biol Blood Marrow Transplant. 1999;5:133-143.
8. Sykes M, Sheard MA, Sachs DH. Graft-versus-host-related immunosuppression is induced in mixed chimeras by alloresponses against either host or donor lymphohematopoietic cells. J Exp Med. 1988;168:2391-2396.
9. Hill RS, Petersen FB, Storb R, et al. Mixed hematologic chimerism after allogeneic marrow transplantation for severe aplastic anemia is associated with a higher risk of graft rejection and a lessened incidence of acute graft-versus-host disease. Blood. 1986;67:811-816.
10. Durnam DM, Anders KR, Fisher L, O'Quigley J, Bryant EM, Thomas ED. Analysis of the origin of marrow cells in bone marrow transplant recipients using a Y-chromosome-specific in situ hybridization assay. Blood. 1989;74:2220-2226.
11. Roy DC, Tantravahi R, Murray C, et al. Natural history of mixed chimerism after bone marrow transplantation with CD6-depleted allogeneic marrow: a stable equilibrium. Blood. 1990;75:296-304.
12. Roux E, Helg C, Chapuis B, Jeannet M, Roosnek E. Evolution of mixed chimerism after allogeneic bone marrow transplantation as determined on granulocytes and mononuclear cells by the polymerase chain reaction. Blood. 1992;79:2775-2783.
13. Cross NC, Feng L, Chase A, Bungey J, Hughes TP, Goldman JM. Competitive polymerase chain reaction to estimate the number of BCR-ABL transcripts in chronic myeloid leukemia patients after bone marrow transplantation. Blood. 1993;82:1929-1936.
14. Colby C, Sykes M, Sachs DH, Spitzer TR. Cellular modulation of acute graft-versus-host disease. Biol Blood Marrow Transplant. 1997;3:287-293.
15. Frassoni F, Strada P, Sessarego M, et al. Mixed chimerism after allogeneic bone marrow transplantation for leukemia: correlation with dose of total body irradiation and graft-versus-host disease. Bone Marrow Transplant. 1990;5:235-240.
16. Chalmers EA, Sproul AM, Mills KI, et al. Effect of radiation on the development of mixed haemopoietic chimerism following T cell-depleted allogeneic bone marrow transplantation. Bone Marron Transplantation. 199210:425-430.
17. Bertheas MF, Lafage M, Levy P, et al. Influence of mixed chimerism on the results of allogeneic bone marrow transplantation for leukemia. Blood. 1991;78:3103-3106.
18. Huss R, Deeg JH, Gooley T, et al. Effect of mixed chimerism on graft-versus-host disease, disease recurrence and survival after HLA-identical marrow transplantation for aplastic anemia or chronic myelogenous leukemia. Bone Marrow Transplant. 1996;18:767-776.
19. Petz LD, Yam P, Wallace RB, et al. Mixed hematopoietic chimerism following bone marrow transplantation for hematologic malignancies. Blood. 1987;70:1331-1337.
20. Giralt SE, Estey E, Albitar M, et al. Engraftment of allogeneic hematopoietic progenitor cells with purine analog-containing chemotherapy: harnessing graft-versus-leukemia without myeloablative therapy. Blood. 1997;89:4531-4536.
21. Khouri IF, Keating M, Korbling M, et al. Transplant-Lite: induction of graft-versus-malignancy using fludarabine-based nonablative chemotherapy and allogeneic blood progenitor-cell transplantation as treatment for lymphoid malignancies. J Clin Oncol. 1998;16:2817-2824.
22. Slavin S, Nagler A, Naparstek E, et al. Nonmyeloablative stem cell transplantation and cell therapy as an alternative to conventional bone marrow transplantation with lethal cytoreduction for the treatment of malignant and nonmalignant hematologic diseases. Blood. 1998;91:756-763.
23. Porter DL, Roth MS, McGarigle C, Ferrara JL, Antin JH. Induction of graft-versus-host disease as immunotherapy for relapsed chronic myeloid leukemia. N Engl J Med. 1994;330:100-106.
24. Mackinnon S, Papadopoulo EB, Carabasi MH, et al. Adoptive immunotherapy evaluating escalating doses of donor leukocytes for relapse of chronic myeloid leukemia following bone marrow transplantation: separation of graft-versus-leukemia responses from graft-versus-host disease. Blood. 1995;86:1261-1268.
25. Kolb H, Holler E. Adoptive immunotherapy with donor lymphocyte transfusions. Curr Opin Oncol. 1997;9:139-145.
26. Sykes M, Preffer F, McAfee S, et al. Mixed lymphohaematopoietic chimerism and graft-versus-host lymphoma effects after non-myeloblative therapy and HLA-mismatched transplantation. Lancet. 1999;353:1755-1779.
27. Schultze JL, Cardoso AA, Freeman GL, et al. Follicular lymphomas can be induced to present alloantigen efficiently: a conceptual model to improve their tumor immunogenicity. Proc Natl Acad Sci U S A. 1995;92:8200-8204.
28. Nakao S, Nakatsumi T, Chuhjo T, et al. Analysis of late graft failure after allogeneic bone marrow transplantation: detection of residual host cells using amplification of variable number of tandem repeats loci. Bone Marrow Transplant. 1992;9:107-111.
29. Kaplan EL, Meier P: Nonparametric estimation from incomplete observations. J Am Stat Assoc. 1958;53:457-481.
30. Cahill RA, Spitzer TR, Mazumder A. Marrow engraftment and clinical manifestations of capillary leak syndrome. Bone Marrow Transplant. 1996;18:177-184.
31. Report from the International Bone Marrow Transplant Registry. Advisory Committee of the International Bone Marrow Transplant Registry. Bone Marrow Transplant. 1989;4:221-228.
32. Sullivan KM, Witherspoon RP, Storb R, Buckner CD, Sanders J, Thomas ED. Long-term results of allogeneic bone marrow transplantation. Transplant Proc. 1989;21(1 pt 3):2926-2928.
33. Thomas E, Buckner C, Banaji M, et al. One hundred patients with acute leukemia treated by chemotherapy, total body irradiation, and allogeneic marrow transplantation. Blood. 1977;49:511-533.
34. Long GD, Amylon MD, Stockerl-Goldstein KE, et al. Fractionated total-body irradiation, etoposide, and cyclophosphamide followed by allogeneic bone marrow transplantation for patients with high-risk or advanced-stage hematological malignancies. Biol Blood Marrow Transplant. 1997;3:324-330.
35. Giralt SA, LeMaistre CF, Vriesendrop HM, et al. Etoposide, cyclophosphamide, total-body irradiation, and allogeneic bone marrow transplantation for hematologic malignancies. J Clin Oncol. 1994;12:1923-1930.
36. Santos GW, Sensenbrenner LL, Burke PJ, et al. The use of cyclophosphamide for clinical marrow transplantation. Transplant Proc. 1972;4:559-564.
37. Powles RL, Morgenstern GR, Kay HE, et al. Mismatched family donor for bone marrow transplantation and acute leukemia. Lancet. 1983;1:612-615.
38. Lokhorst HM, Schattenberg A, Cornelissen JJ. Donor leukocyte infusions are effective in relapsed multiple myeloma after allogeneic bone marrow transplantation. Blood. 1997;90:4206-4211.